Stockscreener 앱 받기
12.21
0.73%
-0.09
시간 외 거래:
12.21
전일 마감가:
$12.30
열려 있는:
$12.37
하루 거래량:
2.02M
Relative Volume:
0.89
시가총액:
$1.95B
수익:
$61.10M
순이익/손실:
$-138.36M
주가수익비율:
-9.0444
EPS:
-1.35
순현금흐름:
$-90.59M
1주 성능:
+2.43%
1개월 성능:
+23.08%
6개월 성능:
+61.29%
1년 성능:
+52.05%
1일 변동 폭
$11.98
$12.37
1주일 범위
$10.58
$12.65
52주 변동 폭
$5.80
$12.65
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
OCUL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
12.21 | 2.17B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix Inc. Stock Poised for Technical ComebackLow Capital High Return Stock Plans Reviewed - beatles.ru
ETF Channel: ITOT Expected to Reach $154 - AInvest
Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report - Yahoo Finance
Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions - TipRanks
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - MSN
Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com
Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Ocular Therapeutix 2025 Q2 Earnings Deepening Losses Amid Strategic Momentum - AInvest
Ocular Therapeutix Reports Second Quarter 2025 Financial Results - VisionMonday.com
Ocular Therapeutix Reports Q2 2025 Financial Results - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix Q2 2025 Sales Down 18%, R&D Expenses Surge 76.9% Amid Reimbursement Pressure - AInvest
OCUL Sales Drop 18% - The Motley Fool
Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress - TipRanks
Ocular Therapeutix Q2 2025: Unpacking Key Contradictions in SOL-R Trial Criteria and FDA Relations - AInvest
Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data - Investing.com Canada
Ocular Therapeutix Q2 2025 Earnings Call Transcript - MarketBeat
Clear Street reiterates Buy rating on Ocular Therapeutix stock at $18 - Investing.com Canada
Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target - Investing.com Canada
Earnings call transcript: Ocular Therapeutix misses Q2 2025 earnings, stock drops - Investing.com
Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Quant Strategy Flags Ocular Therapeutix Inc. for EntryLow Risk Swing Trade Opportunities Identified - beatles.ru
Ocular Therapeutix tumbles as Q2 results miss estimates - Investing.com
Ocular Therapeutix: Can AXPAXLI's Pipeline Offset Financial Headwinds? - AInvest
Ocular Therapeutix Q2 Loss Widens, Revenue Falls; Shares Down Pre-Bell - MarketScreener
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (OCUL) Ocular Therapeutix Posts Q2 Net Loss $0.39 a Share, vs. FactSet Est of $0.35 Loss - MarketScreener
Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com
Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights - TradingView
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q2 Revenue $13.5M, vs. FactSet Est of $13.6M - MarketScreener
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
Ocular Therapeutix raises $97mln, expects cash runway into 2028. - AInvest
What's Next: Ocular Therapeutix's Earnings Preview - 富途牛牛
Ocular Therapeutix stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com Canada
Ocular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
What analysts say about Ocular Therapeutix Inc. stockBuild wealth with high-performing stocks - Jammu Links News
Is Ocular Therapeutix Inc. a growth stock or a value stockHigh-yield investments - Jammu Links News
When is Ocular Therapeutix Inc. stock expected to show significant growthAchieve impressive returns with smart timing - Jammu Links News
What are the latest earnings results for Ocular Therapeutix Inc.Capitalize on market shifts with expert advice - Jammu Links News
How does Ocular Therapeutix Inc. compare to its industry peersBreakout stock performance - Jammu Links News
How does Ocular Therapeutix Inc. generate profit in a changing economyInvest confidently with data-backed picks - Jammu Links News
Is it the right time to buy Ocular Therapeutix Inc. stockTriple-digit growth rates - Jammu Links News
Should I hold or sell Ocular Therapeutix Inc. stock in 2025Capitalize on market trends with expert guidance - Jammu Links News
How volatile is Ocular Therapeutix Inc. stock compared to the marketBuild a diversified portfolio for steady profits - Jammu Links News
What are Ocular Therapeutix Inc. company’s key revenue driversGet daily updates on top-performing stocks - Jammu Links News
Is Ocular Therapeutix Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
What is Ocular Therapeutix Inc. company’s growth strategyAchieve rapid portfolio appreciation - Jammu Links News
How strong is Ocular Therapeutix Inc. company’s balance sheetExtraordinary performance - Jammu Links News
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):